SCHEDULE: Janus Henderson Discloses 2.3% Stake in Soleno Therapeutics

Janus Henderson Group plc has reported beneficial ownership of 1,205,303 common shares, representing 2.3% of the class, in Soleno Therapeutics, Inc. as of April 30, 2026.

Summary

• Janus Henderson Group plc, through its various asset management subsidiaries, has filed a Schedule 13G indicating beneficial ownership of 1,205,303 common shares of Soleno Therapeutics, Inc.
• This holding represents 2.3% of the total class of common shares outstanding.
• The filing is an amendment (Amendment No. 9) to a previous filing, with the event date requiring this statement being April 30, 2026.
• The reporting entity, Janus Henderson Group plc, is a holding company for several SEC-registered investment advisers and their foreign equivalents.
• These asset managers exercise investment and/or voting discretion on behalf of various clients, including investment companies, other investment advisers, and separate accounts.
• While the asset managers may be deemed beneficial owners, they disclaim ownership of dividends and proceeds from the sale of these securities.
• No single managed portfolio owns more than five percent of Soleno Therapeutics, Inc. common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of institutional ownership without providing company performance data or strategic insights.

Positives

• Significant institutional investor presence indicated by Janus Henderson's filing.
• The filing confirms a substantial, though not controlling, stake in Soleno Therapeutics.

Negatives

• The filing does not contain financial performance data or operational updates for Soleno Therapeutics, limiting the assessment of company-specific performance.

Risks

• The filing itself does not present risks related to Soleno Therapeutics' operations or market position. The primary risk is associated with the nature of institutional investment, where significant holdings can be divested, potentially impacting share price.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Soleno Therapeutics' future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. Janus Henderson's filing indicates their ongoing investment strategy in the biotechnology or pharmaceutical sector, where Soleno Therapeutics operates.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor, which can be viewed positively, but also implies potential for market impact if Janus Henderson adjusts its position.

Next Steps

• Janus Henderson Group plc will continue to monitor its holdings in Soleno Therapeutics, Inc. and may file amendments to this Schedule 13G if there are material changes in its beneficial ownership.

Key Dates

Keywords

Schedule 13G, Janus Henderson Group plc, Soleno Therapeutics, Inc., Beneficial Ownership, Common Shares, Institutional Investor, Investment Adviser, SEC Filing, Equity Holding